Cesca Therapeutics Inc. (KOOL)

0.27
NASDAQ : Health Technology
Prev Close 0.27
Day Low/High 0.26 / 0.27
52 Wk Low/High 0.21 / 0.58
Avg Volume 183.80K
Exchange NASDAQ
Shares Outstanding 23.65M
Market Cap 6.31M
EPS -2.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

ThermoGenesis Releases Its Enhanced X-MINI® CD3 Selection Kit For The Research Market

ThermoGenesis Releases Its Enhanced X-MINI® CD3 Selection Kit For The Research Market

- Increased flexibility allows researchers to select CD3+ cells from a sample of whole human peripheral blood -

ThermoGenesis AXP® II And PXP® Systems Now Registered And Available In Thailand

ThermoGenesis AXP® II And PXP® Systems Now Registered And Available In Thailand

RANCHO CORDOVA, Calif., April 10, 2019 /PRNewswire/ -- ThermoGenesis Corp.

Cesca Therapeutics Announces Fiscal 2018 Year End Financial Results And Provides Corporate Update

Cesca Therapeutics Announces Fiscal 2018 Year End Financial Results And Provides Corporate Update

Conference Call to be Held Today at 1:30 p.m. PDT/4:30 p.m. EDT

Cesca Therapeutics To Announce Financial Results For The Fourth Quarter Ended December 31, 2018 And Host Conference Call On March 25

Cesca Therapeutics To Announce Financial Results For The Fourth Quarter Ended December 31, 2018 And Host Conference Call On March 25

RANCHO CORDOVA, Calif., March 20, 2019 /PRNewswire/ -- Cesca Therapeutics Inc.

Cesca Therapeutics To Present At The BIO CEO & Investor Conference

Cesca Therapeutics To Present At The BIO CEO & Investor Conference

RANCHO CORDOVA, Calif., Feb.

ThermoGenesis Corp® Completes Construction And Qualification Of In-House Clean Room For Assembly Of All X-Series™ Cell Processing Disposables

ThermoGenesis Corp® Completes Construction And Qualification Of In-House Clean Room For Assembly Of All X-Series™ Cell Processing Disposables

Transfer from Third Party to In-house Assembly Allows for Greater Control Over Quality, Scale and Costs

Cesca Therapeutics Inc. Announces Release Of X-Mini™ Cell Selection Kit For The CAR-T Research Market

Cesca Therapeutics Inc. Announces Release Of X-Mini™ Cell Selection Kit For The CAR-T Research Market

X-Mini is the first in a series of kits that comprise the company's CAR-TXpress™ platform

Cesca Therapeutics Expands CAR-TXpress™ Intellectual Property Portfolio With Filing Of New Patent Covering Cell Activation & Transduction

Cesca Therapeutics Expands CAR-TXpress™ Intellectual Property Portfolio With Filing Of New Patent Covering Cell Activation & Transduction

Invention further streamlines ThermoGenesis' CAR-TXpress workflow, improving efficiency and reducing costs

Cesca Therapeutics Announces Issuance Of Second Cellular Processing Patent

Cesca Therapeutics Announces Issuance Of Second Cellular Processing Patent

Intellectual Property Position Surrounding the Company's X-BACS Technology is Significantly Strengthened

Cesca Therapeutics Announces Financial Results For The Three Months Ended September 30, 2017 And Provides Corporate Update

Cesca Therapeutics Announces Financial Results For The Three Months Ended September 30, 2017 And Provides Corporate Update

Conference Call to be Held at 4:30 p.m. EST (1:30 p.m. PST)